Nonlinear complexity and spectral analyses of heart rate variability in medicated and unmedicated patients with schizophrenia

Neuropsychobiology

Volumn 51, Issue 1, 2005, Pages 10-15

  Mujica Parodi, L R ^a   Yeragani, Vikram ^b   Malaspina, Dolores ^c,d  

^a STONY BROOK UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^d Columbia University ^*  (United States)

Author keywords

Antipsychotic medication; Cardiac mortality; Heart rate variability; Nonlinear complexity analyses; Schizophrenia; Symbolic dynamics; Sympathetic nervous system; Vagal function

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

ADULT; AGE DISTRIBUTION; ANALYTIC METHOD; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; ELECTROCARDIOGRAM; FEMALE; GENDER; HEART FUNCTION; HEART RATE VARIABILITY; HUMAN; MALE; MENTAL PATIENT; NONLINEAR COMPLEXITY ANALYSIS; PRIORITY JOURNAL; PSYCHOSIS; RR INTERVAL; SAMPLING; SCHIZOPHRENIA; SLEEP; SPECTROSCOPY; STANDARDIZATION; TIME; ANALYSIS OF VARIANCE; CLINICAL TRIAL; COMPARATIVE STUDY; DEMOGRAPHY; DRUG EFFECT; ELECTROCARDIOGRAPHY; HEART RATE; METHODOLOGY; MIDDLE AGED; NONLINEAR SYSTEM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; DEMOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; NONLINEAR DYNAMICS; SCHIZOPHRENIA; SPECTRUM ANALYSIS;

EID: 16444383930     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000082850     Document Type: Article

References (31)

1. Lombardi F: Clinical implications of present physiological understanding of HRV components. Card Electrophysiol Rev 2002;6:245-249.
2. Singh RB, Kartik C, Otsuka K, Pella D, Pella J: Brain-heart connection and the risk of heart attack. Biomed Pharmacother 2002;56(Suppl 2):257s-265s.
3. Tsuji H, Larson MG, Venditti FJ Jr, Manders ES, Evans JC, Feldman CL, Levy D: Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study. Circulation 1996;94:2850-2855.
4. Mueck-Weymann M, Rechlin T, Ehrengut F, Rauh R, Acker J, Dittmann RW, Czekalla J, Joraschky P, Musselman D: Effects of olanzapine and clozapine upon pulse rate variability. Depress Anxiety 2002;16:93-99.
5. Cohen H, Loewenthal U, Matar M, Kotler M: Heart rate variability in schizophrenic patients treated with antipsychotic agents. Harefuah 2001;140:1142-1147.
6. Rechlin T, Beck G, Weis M, Kaschka WP: Correlation between plasma clozapine concentration and heart rate variability in schizophrenic patients. Psychopharmacology (Berl) 1998;135:338-341.
7. Czekalla J, Kollack-Walker S, Beasley CM Jr: Cardiac safety parameters of olanzapine: Comparison with other atypical and typical antipsychotics. J Clin Psychiatry 2001;62(suppl 2):35-40.
8. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH: QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000;355:1048-1052.
9. Agelink MW, Majewski T, Wurthmann C, Lukas K, Ullrich H, Linka T, Klieser E: Effects of newer atypical antipsychotics on autonomic neurocardiac function: A comparison between amisulpride, olanzapine, sertindole, and clozapine. J Clin Psychopharmacol 2001;21:8-13.
10. Nuechterlein KH, Dawson ME, Gitlin M, Ventura J, Goldstein MJ, Snyder KS, Yee CM, Mintz J: Developmental processes in schizophrenic disorders: Longitudinal studies of vulnerability and stress. Schizophr Bull 1992;18:387-425.
11. Grossberg S: The imbalanced brain: From normal behavior to schizophrenia. Biol Psychiatry 2000;48:81-98.
12. Venables PH: The Emanuel Miller memorial lecture 1987. Childhood markers for adult disorders. J Child Psychol Psychiatry 1989;30:347-364.
13. Henmi Y: Prodromal symptoms of relapse in schizophrenic outpatients: Retrospective and prospective study. Jpn J Psychiatry Neurol 1993;47:753-775.
14. Doering S, Muller E, Kopcke W, Pietzcker A, Gaebel W, Linden M, Muller P, Muller-Spahn F, Tegeler J, Schussler G: Predictors of relapse and rehospitalization in schizophrenia and schizoaffective disorder. Schizophr Bull 1998;24:87-98.
15. Tandon R, Mazzara C, DeQuardo J, Craig KA, Meador-Woodruff JH, Goldman R, Greden JF: Dexamethasone suppression test in schizophrenia: Relationship to symptomatology, ventricular enlargement, and outcome. Biol Psychiatry 1991;29:953-964.
16. Lindstrom LH: Clinical and biological markers for outcome in schizophrenia: A review of a longitudinal follow-up study in Uppsala schizophrenia research project. Neuropsychopharmacology 1996;14(3 suppl):23S-26S.
17. Dawson ME, Schell AM: What does electrodermal activity tell us about prognosis in the schizophrenia spectrum? Schizophr Res 2002;54:87-93.
18. Bernstein AS, Taylor KW, Starkey P, Juni S, Lubowsky J, Paley H: Bilateral skin conductance, finger pulse volume, and EEG orienting response to tones of differing intensities in chronic schizophrenics and controls. J Nerv Ment Dis 1981;169:513-528.
19. Kurths J, Voss A, Saparin P, Witt A, Kleiner HJ, Wessel N: Quantitative analysis of heart rate variability. Chaos 1995;5:88-94.
20. Voss A, Kurths J, Kleiner HJ, Witt A, Wessel N, Saparin P, Osterziel KJ, Schurath R, Dietz R: The application of methods of non-linear dynamics for the improved and predictive recognition of patients threatened by sudden cardiac death. Cardiovasc Res 1996;31:419-433.
21. Yeragani VK, Nadella R, Hinze B, Yeragani S, Jampala VC: Nonlinear measures of heart period variability: Decreased measures of symbolic dynamics in patients with panic disorder. Depress Anxiety 2000;12:67-77.
22. Nurnberger JI Jr, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG, Harkavy-Friedman J, Severe JB, Malaspina D, Reich T: Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch Gen Psychiatry 1994;51:849-859; discussion 863-864.
23. Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276.
24. Akselrod S, Gordon D, Ubel FA, Shannon DC, Berger AC, Cohen RJ: Power spectrum analysis of heart rate fluctuation: A quantitative probe of beat-to-beat cardiovascular control. Science 1981;213:220-222.
25. Pagani M, Montano N, Porta A, Malliani A, Abboud FM, Birkett C, Somers VK: Relationship between spectral components of cardiovascular variabilities and direct measures of muscle sympathetic nerve activity in humans. Circulation 1997;95:1441-1448.
26. Benca RM: Sleep in psychiatric disorders. Neurol Clin 1996;14:739-764.
27. Yeragani VK, Sobolewski E, Igel G, Johnson C, Jampala VC, Kay J, Hillman N, Yeragani S, Vempati S: Decreased heart-period variability in patients with panic disorder: A study of Holter ECG records. Psychiatry Res 1998;78:89-99.
28. Okada T, Toichi M, Sakihama M: Influences of an anticholinergic antiparkinsonian drug, parkinsonism, and psychotic symptoms on cardiac autonomic function in schizophrenia. J Clin Psychopharmacol 2003;23:441-447.
29. Toichi M, Kubota Y, Murai T, Kamio Y, Sakihama M, Toriuchi T, Inakuma T, Sengoku A, Miyoshi K: The influence of psychotic states on the autonomic nervous system in schizophrenia. Int J Psychophysiol 1999;31:147-154.
30. Bigger JT Jr, Fleiss JL, Steinman RC, Rolnitzky LM, Kleiger RE, Rottman JN: Frequency domain measures of heart period variability and mortality after myocardial infarction. Circulation 1992;85:164-171.
31. Mujica-Parodi LR, Corcoran C, Greenberg T, Sackein H, Malaspina D: Are cognitive symptoms of schizophrenia mediated by abnormalities in emotional arousal? CNS Spectr 2002;7:58-69.